rts logo

Seres Therapeutics Inc (MCRB) Stock Could Soon Reward Patient Investors

Seres Therapeutics Inc (NASDAQ: MCRB) is -50.00% lower on its value in year-to-date trading and has touched a low of $0.54 and a high of $2.05 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MCRB stock was last observed hovering at around $0.70 in the last trading session, with the day’s loss setting it 0.0%.

Currently trading at $0.70, the stock is -13.15% and -21.17% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.49 million and changing -0.70% at the moment leaves the stock -25.71% off its SMA200. MCRB registered -53.02% loss for a year compared to 6-month gain of -22.99%. The firm has a 50-day simple moving average (SMA 50) of $0.888 and a 200-day simple moving average (SMA200) of $0.942225.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The stock witnessed a -23.82% loss in the last 1 month and extending the period to 3 months gives it a -44.44%, and is -13.96% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.42% over the week and 8.90% over the month.

Seres Therapeutics Inc (MCRB) has around 233 employees, a market worth around $119.14M and $0.37M in sales. Profit margin for the company is -43343.58%. Distance from 52-week low is 29.63% and -65.85% from its 52-week high. The company has generated returns on investments over the last 12 months (-139.32%).

The EPS is expected to grow by 11.81% this year, but quarterly earnings will post -97.10% year-over-year.

Seres Therapeutics Inc (MCRB) Top Institutional Holders

110.0 institutions hold shares in Seres Therapeutics Inc (MCRB), with institutional investors hold 47.54% of the company’s shares. The shares outstanding are 135.04M, and float is at 118.98M with Short Float at 15.17%. Institutions hold 41.26% of the Float.

The top institutional shareholder in the company is FLAGSHIP PIONEERING INC. with over 23.12 million shares valued at $16.73 million. The investor’s holdings represent 15.8226% of the MCRB Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 22.72 million shares valued at $16.44 million to account for 15.5489 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 6.29 million shares representing 4.3023% and valued at over $4.55 million, while TANG CAPITAL MANAGEMENT LLC holds 1.6476 of the shares totaling 2.41 million with a market value of $1.74 million.

Seres Therapeutics Inc (MCRB) Insider Activity

The most recent transaction is an insider sale by DesRosier Thomas, the company’s Chief Legal Officer and EVP. SEC filings show that DesRosier Thomas sold 873 shares of the company’s common stock on Aug 16 ’24 at a price of $0.84 per share for a total of $733.0. Following the sale, the insider now owns 0.12 million shares.

Seres Therapeutics Inc disclosed in a document filed with the SEC on Aug 16 ’24 that von Moltke Lisasold a total of 973 shares of the company’s common stock. The trade occurred on Aug 16 ’24 and was made at $0.84 per share for $817.0. Following the transaction, the insider now directly holds 21013.0 shares of the MCRB stock.

Still, SEC filings show that on Aug 16 ’24, Henn Matthew R. () disposed off 923 shares at an average price of $0.84 for $775.0. The insider now directly holds 67,247 shares of Seres Therapeutics Inc (MCRB).

Related Posts